GlassScriptPhysician profile
Celeste S Soberano
NPI 1285625467
$583.55
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $110 · 2021: $176 · 2022: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $172.25 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $130.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.10 | 2019-2022 | |
| Abbvie INC. | $72.53 | 2019-2022 | |
| Lilly USA, LLC | $47.30 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $29.02 | 2019-2022 | |
| Novo Nordisk INC | $18.16 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.84 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Soberano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.